Am­gen en­lists En­tera in a drug dis­cov­ery pact; Boehringer brings out the bud­get ax

→ Am­gen has hand­ed a “mod­est” tech trans­fer fee over to En­tera $EN­TX to get them start­ed on a dis­cov­ery pact fo­cused on in­flam­ma­to­ry dis­eases, plus oth­er ail­ments. En­tera could al­so get up to $270 mil­lion in mile­stones for the pact with Am­gen, de­signed to get the Is­raeli com­pa­ny to use its plat­form tech to “de­vel­op oral for­mu­la­tions for one pre­clin­i­cal large mol­e­cule pro­gram that Am­gen has se­lect­ed. Am­gen al­so has an op­tion to se­lect up to two ad­di­tion­al pro­grams to in­clude in the col­lab­o­ra­tion.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER